雷贝拉唑对氯吡格雷抗血小板聚集作用的影响

被引：4

作者：

马腾

王斌

机构：

[1] 北京大学航天临床医学院心脏中心

来源：

中国介入心脏病学杂志 | 2010年 / 18卷 / 04期

关键词：

氯吡格雷; 质子泵抑制剂; 雷贝拉唑; 细胞色素P450酶系统; 血小板聚集;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

目的探讨择期经皮冠状动脉介入治疗(PCI)术的患者中,质子泵抑制剂雷贝拉唑对氯吡格雷的血小板聚集率的影响。方法入组120例行择期PCI的冠心病患者,按照病案号的单双号随机分为雷贝拉唑组和对照组。对照组按常规服用阿司匹林、氯吡格雷口服和其他PCI术前准备,雷贝拉唑组在PCI术后加用雷贝拉唑(20mg/d)共7d。比较两组住院期间7d后血小板聚集率以及PCI术后1个月内临床事件的发生率、便潜血的阳性率。结果雷贝拉唑组和对照组二磷酸腺苷(adenosine diphosphate,ADP)诱导的血小板聚集率分别为32.4%和37.1%(P=0.1971),心肌缺血的发生率分别为3.3%和5.0%(P=0.6478),均未发生严重不良临床事件。雷贝拉唑组和对照组便潜血阳性率分别为0%和6.7%(P=0.0419),PCI术后1月随访时便潜血阳性率分别为0%和8.3%(P=0.0224)。结论合用雷贝拉唑对氯吡格雷的抗血小板聚集作用没有明显影响,同时具有保护消化道、减少消化道出血的机会。

引用

页码：207 / 212

页数：6

共 6 条

[1]

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials[J] . Michelle L O’Donoghue,Eugene Braunwald,Elliott M Antman,Sabina A Murphy,Eric R Bates,Yoseph Rozenman,Alan D Michelson,Raymond W Hautvast,Peter N Ver Lee,Sandra L Close,Lei Shen,Jessica L Mega,Marc S Sabatine,Stephen D Wiviott.The Lancet . 2009 (9694)

[2] A population-based study of the drug interaction between proton pump inhibitors and clopidogrel [J].

Juurlink, David N. ;

Gomes, Tara ;

Ko, Dennis T. ;

Szmitko, Paul E. ;

Austin, Peter C. ;

Tu, Jack V. ;

Henry, David A. ;

Kopp, Alex ;

Mamdani, Muhammad M. .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2009, 180 (07) :713-718

[3] Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin [J].

Gilard, Martine ;

Arnaud, Bertrand ;

Cornily, Jean-Christophe ;

Le Gal, Gregoire ;

Lacut, Karine ;

Le Calvez, Genevive ;

Mansourati, Jacques ;

Mottier, Dominique ;

Abgrall, Jean-Francois ;

Boschat, Jacques .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (03) :256-260

[4] CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects [J].

Sakai, T ;

Aoyama, N ;

Kita, T ;

Sakaeda, T ;

Nishiguchi, K ;

Nishitora, Y ;

Hohda, T ;

Sirasaka, D ;

Tamura, T ;

Tanigawara, Y ;

Kasuga, M ;

Okumura, K .

PHARMACEUTICAL RESEARCH, 2001, 18 (06) :721-727

[5]

Proton pump inhibitors and their drug interactions: an evidence-based approach[J] . Lauren B. Gerson,George Triadafilopoulos.European Journal of Gastroenterology ＆ Hepatology . 2001 (5)

[6]

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs[J] . Urs A. Meyer.European Journal of Gastroenterology ＆ Hepatology . 1996

← 1 →